Poster (Scientific congresses and symposiums)
Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time.
VIEUJEAN, Sophie; LOUIS, Edouard; REENAERS, Catherine
201830th edition of Belgian Week of Gastroenterology
Peer reviewed
 

Files


Full Text
Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis - IBD Research.pdf
Publisher postprint (1.28 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
General & internal medicine
Author, co-author :
VIEUJEAN, Sophie  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
LOUIS, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
REENAERS, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
Language :
English
Title :
Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time.
Publication date :
February 2018
Event name :
30th edition of Belgian Week of Gastroenterology
Event date :
du 21 février 2018 au 23 février 2018
Peer reviewed :
Peer reviewed
Available on ORBi :
since 28 May 2019

Statistics


Number of views
56 (1 by ULiège)
Number of downloads
18 (0 by ULiège)

Bibliography


Similar publications



Sorry the service is unavailable at the moment. Please try again later.
Contact ORBi